Enfusion upgraded by Morgan Stanley with a new price target
$ENFN
Computer Software: Prepackaged Software
Technology
Morgan Stanley upgraded Enfusion from Equal-Weight to Overweight and set a new price target of $12.00 from $13.00 previously
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 5/10/2024 | $11.00 | Overweight | Morgan Stanley |
| 2/28/2024 | $9.00 → $8.00 | Neutral → Sell | Goldman |
| 1/30/2024 | $11.00 → $9.00 | Neutral → Underweight | JP Morgan |
| 11/7/2023 | $9.00 | Neutral | UBS |
| 4/3/2023 | $11.00 | Neutral | Piper Sandler |
| 3/15/2023 | $12.00 | Neutral | JP Morgan |
| 1/4/2023 | $15.00 → $10.00 | Neutral → Underperform | BofA Securities |
| 1/3/2023 | $13.00 → $12.00 | Equal-Weight → Overweight | Morgan Stanley |
Enfusion, Inc. ("Enfusion") (NYSE:ENFN), a leading provider of software-as-a-service (SaaS) solutions for investment managers, today announced financial results for the fourth quarter and full year ended December 31, 2024. Fourth Quarter 2024 Financial Highlights: Total revenue was $52.9 million, up 13.9% compared to the same period in the prior year. Gross Profit was $36.5 million with a Gross Profit Margin of 69.0%. Adjusted Gross Profit was $36.9 million with an Adjusted Gross Profit Margin of 69.6%. Net Income was $0.2 million with a Net Income Margin of 0.3%. Adjusted EBITDA was $12.3 million, up 25.3% compared to the same period in the prior year. Operating Cash Fl
Clearwater Analytics Holdings, Inc. (NYSE:CWAN) ("Clearwater" or the "Company"), a leading worldwide provider of SaaS-based investment management, accounting, reporting, and analytics solutions, and Enfusion, Inc. (NYSE:ENFN) ("Enfusion"), a leader in software-as-a-service solutions for the investment management and hedge fund industry, today announced the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (the "HSR Act"), in connection with Clearwater's previously announced proposed acquisition of Enfusion. The expiration of the waiting period occurred at 11:59 p.m. on February 24, 2025. The expiration of the waiting period under the HSR Act s
Clearwater Analytics Holdings, Inc. (NYSE:CWAN), ("Clearwater" or the "Company"), a leading worldwide provider of SaaS-based investment management, accounting, reporting, and analytics solutions, today announced that it is launching a proposed senior secured Term Loan B Facility due 2033 in an aggregate principal amount of $800.0 million (the "Term Loan"). Clearwater intends to use proceeds from the Term Loan, together with the issuance of equity, to fund the previously announced acquisition of Enfusion, Inc. (NYSE:ENFN) ("Enfusion") for a total transaction price of approximately $1.5 billion. About Clearwater Analytics Clearwater Analytics (NYSE:CWAN), a global, industry-leading SaaS
Enfusion, Inc. ("Enfusion") (NYSE:ENFN), a leading provider of software-as-a-service (SaaS) solutions for investment managers, today announced financial results for the fourth quarter and full year ended December 31, 2024. Fourth Quarter 2024 Financial Highlights: Total revenue was $52.9 million, up 13.9% compared to the same period in the prior year. Gross Profit was $36.5 million with a Gross Profit Margin of 69.0%. Adjusted Gross Profit was $36.9 million with an Adjusted Gross Profit Margin of 69.6%. Net Income was $0.2 million with a Net Income Margin of 0.3%. Adjusted EBITDA was $12.3 million, up 25.3% compared to the same period in the prior year. Operating Cash Fl
Investor Conference Call Scheduled for Today at 8:30 a.m. ET Clearwater Analytics (NYSE:CWAN) ("Clearwater") and Enfusion, Inc. (NYSE:ENFN) ("Enfusion") today announced their entry into a definitive merger agreement for Clearwater to acquire Enfusion, a leader in software-as-a-service (SaaS) solutions for the investment management and hedge fund industry. The purchase price is $11.25 per share, delivered in an approximately equal mix of cash and stock. Additionally, Clearwater will pay $30 million to terminate Enfusion's tax receivable agreement (TRA). This equates to a purchase price of approximately $1.5 billion. This press release features multimedia. View the full release here: https
Enfusion, Inc. ("Enfusion") (NYSE:ENFN), a leading provider of software-as-a-service (SaaS) solutions for investment managers, has posted its third quarter 2024 financial results as part of its Q3 2024 Shareholder Letter which can be viewed by navigating to the Financials section of its Investor Relations website at http://ir.enfusion.com. 3Q24 Earnings Conference Call Management will host a conference call today, November 4, 2024, at 8:30 AM ET to discuss the results. To pre-register for the live teleconference of the second quarter earnings call, please use this link. To access this call, dial (888) 596-4144. The conference ID number is 9652536. The earnings conference call will also
4 - Enfusion, Inc. (0001868912) (Issuer)
4 - Enfusion, Inc. (0001868912) (Issuer)
4 - Enfusion, Inc. (0001868912) (Issuer)
Morgan Stanley resumed coverage of Enfusion with a rating of Overweight and set a new price target of $11.00
Goldman downgraded Enfusion from Neutral to Sell and set a new price target of $8.00 from $9.00 previously
JP Morgan downgraded Enfusion from Neutral to Underweight and set a new price target of $9.00 from $11.00 previously
SC 13G/A - Enfusion, Inc. (0001868912) (Subject)
SC 13G/A - Enfusion, Inc. (0001868912) (Subject)
SC 13G/A - Enfusion, Inc. (0001868912) (Subject)
425 - Enfusion, Inc. (0001868912) (Subject)
DEFA14A - Enfusion, Inc. (0001868912) (Filer)
DEFM14A - Enfusion, Inc. (0001868912) (Filer)
FTV Capital, a leading sector-focused growth equity investment firm, today announced its inclusion for the fourth consecutive year on Inc.'s annual Founder-Friendly Investors list, which honors the private equity, venture capital firms and lenders with a track record of backing founder-led companies. This year's list recognizes 269 firms that believe in backing founder-led businesses and helping them thrive, demonstrated by their successful track records of collaboration and remaining actively involved with their portfolio companies to drive growth. "We are honored to be recognized again by Inc. for our ongoing commitment to serving as a collaborative, strategic partner to founders and ent
Appointments of Arman Artuc to Head of Engineering, and Jesper Cordes to Head of Client Services Americas, Will Further Elevate Enfusion's Operations as an Investment Technology Industry Leader Enfusion, Inc. ("Enfusion") (NYSE:ENFN), a leading provider of software-as-a-service (SaaS) solutions for investment managers, announced today the appointments of Arman Artuc to Head of Engineering and Jesper Cordes to Head of Client Services Americas. These additions to the leadership team reinforce the company's position as a global leader in investment technology and services, which enables Enfusion to continue to attract top-performing industry experts and innovators to its ranks. Enfusion is s
Transformative acquisition will position ZEMA as global leader in offering high-quality enterprise data management and analytics for the energy and commodities industry ZEMA Global Data Corporation (formerly ZE PowerGroup), a leading provider of enterprise data management and analytics for the commodity and energy sectors, today announced its plans to acquire Morningstar Commodity Data, a provider of commodities and energy data and insights. The transaction is expected to close later this month. The business will serve a diverse portfolio of over 200 enterprises with an expanded product offering and broader geographic operations to support customers around the world. The announcement come